2025-521962-83-00RecruitingPhase 2
AdaptNK –Cell Therapy for High-risk Myeloid Disease
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Sponsor
- Karolinska Institutet
- Enrollment
- 26
- Locations
- 2
Study Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 65+ years (65+ Years, 18-64 Years)
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Karl-Johan Malmberg
Scientific
Karolinska Institutet
Study Sites (2)
Loading locations...
Similar Trials
Active, not recruiting
Phase 1
Exploratory Clinical Study on Memory NK Cell Therapy for Advanced Metastatic Solid TumorsNCT07274449The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School6
Recruiting
Phase 1
Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin LymphomaNCT07283679M.D. Anderson Cancer Center30
Not yet recruiting
Phase 2
Clinical Study on Maintenance Therapy With Selinexor Combined With Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for NK/T-cell LymphomaNCT07276698Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine39
Recruiting
Phase 2
Clinical trial of infusion of activated NK cells for the treatment of children, adolescents and young adults with sarcomas.2024-513431-25-00Hospital Universitario La Paz, Hospital Universitario La Paz10
Recruiting
Phase 2
AML-NET : Acute Myeloid Leukemia treated with with NETrin Abs in combination with [AZACITIDINE + VENETOCLAX]2023-503408-10-00Centre Leon Berard, Centre Leon Berard35